Celldex Therapeutics, Inc. (NASDAQ:CLDX) Receives $62.25 Consensus Target Price from Analysts

Celldex Therapeutics, Inc. (NASDAQ:CLDX) has been assigned an average rating of “Moderate Buy” from the eight analysts that are covering the stock, MarketBeat reports. Two analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $62.25.

A number of analysts have issued reports on the company. Citigroup started coverage on Celldex Therapeutics in a research report on Monday, October 7th. They issued a “buy” rating and a $70.00 target price for the company. Cantor Fitzgerald restated an “overweight” rating and issued a $67.00 price objective on shares of Celldex Therapeutics in a research note on Thursday, January 2nd. Finally, HC Wainwright reiterated a “buy” rating and issued a $80.00 target price on shares of Celldex Therapeutics in a research note on Thursday, December 19th.

Insider Activity

In other news, CEO Anthony S. Marucci purchased 11,500 shares of the business’s stock in a transaction on Monday, November 11th. The stock was purchased at an average cost of $26.82 per share, with a total value of $308,430.00. Following the acquisition, the chief executive officer now directly owns 40,284 shares in the company, valued at approximately $1,080,416.88. This trade represents a 39.95 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 3.80% of the stock is owned by company insiders.

Institutional Investors Weigh In On Celldex Therapeutics

Several large investors have recently added to or reduced their stakes in the business. Wellington Management Group LLP increased its stake in Celldex Therapeutics by 14.5% in the 3rd quarter. Wellington Management Group LLP now owns 9,243,599 shares of the biopharmaceutical company’s stock worth $314,190,000 after acquiring an additional 1,167,659 shares during the last quarter. Bellevue Group AG grew its holdings in shares of Celldex Therapeutics by 3.4% during the third quarter. Bellevue Group AG now owns 3,071,615 shares of the biopharmaceutical company’s stock worth $104,404,000 after purchasing an additional 100,000 shares in the last quarter. Point72 Asset Management L.P. increased its position in shares of Celldex Therapeutics by 51.0% in the second quarter. Point72 Asset Management L.P. now owns 1,937,991 shares of the biopharmaceutical company’s stock worth $71,725,000 after purchasing an additional 654,194 shares during the last quarter. Geode Capital Management LLC raised its stake in Celldex Therapeutics by 0.4% in the third quarter. Geode Capital Management LLC now owns 1,540,513 shares of the biopharmaceutical company’s stock valued at $52,372,000 after purchasing an additional 6,557 shares in the last quarter. Finally, Marshall Wace LLP lifted its position in Celldex Therapeutics by 53.3% during the second quarter. Marshall Wace LLP now owns 1,377,868 shares of the biopharmaceutical company’s stock valued at $50,995,000 after purchasing an additional 479,068 shares during the last quarter.

Celldex Therapeutics Stock Up 0.3 %

CLDX opened at $24.62 on Wednesday. Celldex Therapeutics has a twelve month low of $22.17 and a twelve month high of $53.18. The company’s 50-day moving average price is $25.66 and its two-hundred day moving average price is $31.32. The stock has a market cap of $1.63 billion, a price-to-earnings ratio of -9.58 and a beta of 1.62.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.